The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review

[1]  B. Dong,et al.  Advances and perspectives of PARP inhibitors , 2019, Experimental Hematology & Oncology.

[2]  Anping Li,et al.  Prospects for combining immune checkpoint blockade with PARP inhibition , 2019, Journal of Hematology & Oncology.

[3]  P. Konstantinopoulos,et al.  Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer. , 2019, Trends in cancer.

[4]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[5]  Xuan Jiang,et al.  Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer , 2019, Cancer management and research.

[6]  J. Ledermann,et al.  Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Grant,et al.  3-Methylcholanthrene Induces Chylous Ascites in TCDD-Inducible Poly-ADP-Ribose Polymerase (Tiparp) Knockout Mice , 2019, International journal of molecular sciences.

[8]  B. Price,et al.  Multiple Roles for Mono- and Poly(ADP-Ribose) in Regulating Stress Responses. , 2019, Trends in genetics : TIG.

[9]  K. Tewari,et al.  Targeted treatment of advanced ovarian cancer: spotlight on rucaparib , 2018, Therapeutics and clinical risk management.

[10]  A. D’Andrea.  Mechanisms of PARP inhibitor sensitivity and resistance. , 2018, DNA repair.

[11]  S. Fox,et al.  Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma , 2018, Nature Communications.

[12]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[13]  V. Gebski,et al.  Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. , 2018, The Lancet. Oncology.

[14]  Anne-Claude Gingras,et al.  The Shieldin complex mediates 53BP1-dependent DNA repair , 2018, Nature.

[15]  F. Saad,et al.  Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. , 2018, The Lancet. Oncology.

[16]  George-Lucian Moldovan,et al.  PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress , 2018, bioRxiv.

[17]  L. Rubinstein,et al.  Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors. , 2018 .

[18]  Chunaram Choudhary,et al.  DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity , 2018, Cell.

[19]  W. Symmans,et al.  Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[20]  Michael C. Ostrowski,et al.  Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent , 2018, Molecular Cancer Research.

[21]  G. Mills,et al.  BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. , 2018, Cancer cell.

[22]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, The New England journal of medicine.

[23]  Andrew J. Wilson,et al.  BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. , 2017, Cell reports.

[24]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[25]  S. Tavaré,et al.  Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer , 2017, Nature Communications.

[26]  Lin Zhang,et al.  Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition , 2017, Science Translational Medicine.

[27]  P. Lønning,et al.  Genomic Evolution of Breast Cancer Metastasis and Relapse , 2017, Cancer cell.

[28]  S. Fosmire,et al.  A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia , 2017, Molecular Cancer Therapeutics.

[29]  S. Jackson,et al.  ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. , 2017, Molecular cell.

[30]  James X. Sun,et al.  Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. , 2017, Cancer discovery.

[31]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[32]  G. Mills,et al.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers , 2017, Science Translational Medicine.

[33]  Wenjun Chang,et al.  Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer , 2017, Science Signaling.

[34]  J. Schellens,et al.  Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer , 2017, Clinical Cancer Research.

[35]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[36]  W. Kraus,et al.  PARP Inhibitors for Cancer Therapy , 2017, Cell.

[37]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[38]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[39]  A. Richardson,et al.  CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. , 2016, Cell reports.

[40]  D. Matei,et al.  Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. , 2016, The Lancet. Oncology.

[41]  Y. Pommier,et al.  Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action , 2016, Science Translational Medicine.

[42]  D. Backos,et al.  Targeting WEE1 Kinase in Cancer. , 2016, Trends in pharmacological sciences.

[43]  S. Cantor,et al.  Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells , 2016, Nature.

[44]  D. Levine,et al.  Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. , 2016, Cell reports.

[45]  Chien-Liang Liu,et al.  Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors , 2016, Nature Medicine.

[46]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[47]  R. Verhaak,et al.  Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. , 2015, Journal of the National Cancer Institute.

[48]  K. Schalper,et al.  Basic Overview of Current Immunotherapy Approaches in Cancer. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[49]  G. Shapiro,et al.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.

[50]  J. Garber,et al.  PARP inhibitors in the management of breast cancer: current data and future prospects , 2015, BMC Medicine.

[51]  C. Porter,et al.  AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair , 2015, Oncotarget.

[52]  P. Gimotty,et al.  CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer , 2015, Cancer Immunology Research.

[53]  M. Rubin,et al.  Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. , 2015, Molecular cell.

[54]  Peter Bouwman,et al.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition , 2015, Nature.

[55]  C. Scott,et al.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[57]  S. Jackson,et al.  CtIP tetramer assembly is required for DNA-end resection and repair , 2014, Nature Structural &Molecular Biology.

[58]  H. Mackay,et al.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. , 2015, The Lancet. Oncology.

[59]  S. Keir,et al.  Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program , 2014, Clinical Cancer Research.

[60]  N. Curtin,et al.  Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase , 2014, British Journal of Cancer.

[61]  I. Matic,et al.  Family-wide analysis of poly(ADP-ribose) polymerase activity , 2014, Nature Communications.

[62]  Michael D. Taylor,et al.  Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma , 2014, Molecular Cancer.

[63]  Ryan Emerson,et al.  CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.

[64]  L. Karnitz,et al.  Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors* , 2014, The Journal of Biological Chemistry.

[65]  Jinming Gao,et al.  Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. , 2014, Critical reviews in eukaryotic gene expression.

[66]  Alan Ashworth,et al.  Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. , 2014, Cancer research.

[67]  G. Shapiro,et al.  Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance , 2013, Proceedings of the National Academy of Sciences.

[68]  Jijin Gu,et al.  Enhanced antitumor efficacy by methotrexate conjugated Pluronic mixed micelles against KBv multidrug resistant cancer. , 2013, International journal of pharmaceutics.

[69]  A. Heijink,et al.  Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination , 2013, Oncogene.

[70]  Yair Benita,et al.  Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy , 2013, Molecular Cancer Therapeutics.

[71]  Tian Xia,et al.  Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. , 2013, ACS nano.

[72]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[73]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[74]  E. Yang,et al.  Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition. , 2012, Cancer research.

[75]  Michael Peyton,et al.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.

[76]  S. Bates,et al.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[77]  D. Gao,et al.  Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and novel therapeutic target in acute myeloid leukemia , 2011, Leukemia.

[78]  M. Ranson,et al.  Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study , 2012, Investigational New Drugs.

[79]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[80]  Jernej Ule,et al.  The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. , 2011, Genes & development.

[81]  Vladimir P Torchilin,et al.  Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. , 2011, International journal of pharmaceutics.

[82]  R. Medema,et al.  Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease , 2011, The Journal of cell biology.

[83]  Hong Wang,et al.  p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. , 2011, Cancer research.

[84]  Forrest M Kievit,et al.  Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[85]  A. Ashworth,et al.  Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.

[86]  A. Maitra,et al.  MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts , 2011, Clinical Cancer Research.

[87]  M. Toulmonde,et al.  A review of PARP inhibitors: from bench to bedside. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  M. Gorospe,et al.  miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. , 2011, Molecular cell.

[89]  J. Herman,et al.  BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[91]  Jeremy M. Stark,et al.  53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.

[92]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[93]  M. Yaffe,et al.  Exploiting synthetic lethal interactions for targeted cancer therapy , 2009, Cell cycle.

[94]  T. Helleday,et al.  PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination , 2009, The EMBO journal.

[95]  Maximina H. Yun,et al.  CtIP-BRCA1 modulates the choice of DNA double-strand break repair pathway throughout the cell cycle , 2009, Nature.

[96]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[97]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[98]  Alexander V Kabanov,et al.  Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[99]  C. James,et al.  Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma , 2008, Clinical Cancer Research.

[100]  B. Karlan,et al.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.

[101]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[102]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[103]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[104]  E. Friedberg.  A brief history of the DNA repair field , 2008, Cell Research.

[105]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[106]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[107]  Drew M. Pardoll,et al.  Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.

[108]  S. Keir,et al.  Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft , 2005, Molecular Cancer Therapeutics.

[109]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[110]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[111]  N. Curtin,et al.  PARP inhibitors for cancer therapy , 2005, Expert Reviews in Molecular Medicine.

[112]  Zhihui Feng,et al.  DNA Damage Induces p53-dependent BRCA1 Nuclear Export* , 2004, Journal of Biological Chemistry.

[113]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[114]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[115]  C. Leonetti,et al.  Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. , 2002, Blood.

[116]  M. Kastan,et al.  The many substrates and functions of ATM , 2000, Nature Reviews Molecular Cell Biology.

[117]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[118]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.